Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents strong strategic and operational positives — accelerated partner and program additions, multiple platform launches (OmniUltra and xPloration), significant contracted milestone backlog (> $3B) and demonstrated cost discipline — all of which support a path toward royalty-driven recurring revenue. Offsetting risks include meaningful year‑over‑year revenue declines in 2025, continued net losses, program attrition, nascent instrument-based revenue today, and milestone timing uncertainty that prevents a precise breakeven timetable. On balance the momentum in partner/program growth, new technologies and sizable contracted milestones outweigh the nearer-term financial softness and timing risks.Company Guidance
Partner and Program Growth
Ended 2025 with 107 partners and 407 active programs (net increase of 44 programs). Added 84 programs in 2025 — >20% more than 2024. Over 98% of active programs have contracted future economics to OmniAb.
Large Contracted Milestone and Royalty Backlog
OmniAb reports >$3.0 billion in total contracted milestone payments across active antibody programs and an average portfolio royalty rate of ~3.4%.
Program Progression and Clinical Momentum
25 program advancement events in 2025: 16 programs advanced discovery→preclinical, 4 advanced preclinical→Phase I, and 1 reached registration; 32 active clinical or approved programs at year-end. Clinical-stage programs carry >$350 million in remaining contracted milestone payments. Notable partner updates include Immunovant IMVT-1402 (multiple registrational/POC readouts 2026–2027), Teva TEV-408 funding support (up to $500M via Royalty Pharma) and Merck KGaA advancing M9140 to Phase III (anticipated start H1 2026).
New Platform Launches — OmniUltra and xPloration
Launched OmniUltra (transgenic chicken platform expressing ultra-long CDRH3 on human framework) in Dec 2025 to expand into peptide and picobody opportunities and broaden addressable market (management cited outreach to well over ~130 new potential companies). Launched xPloration partner access program (high-throughput single B-cell screening) in May 2025; deployed 2 instruments by year-end and generated ~ $800k revenue in 2025 from xPloration.
Disciplined Cost Management
Operating expense improvements: Q4 operating expense decreased to $24.1M from $26.7M (Q4 2024). Full‑year 2025 operating expense fell to $87.6M from $100.9M (2024). R&D down to $47.8M (from $55.1M) and G&A down to $29.2M (from $30.7M). Implemented workforce reduction of 22 employees to realize savings going forward.
Clear 2026 Financial Guidance and Path to Cash-Flow Positivity
Guidance for 2026: revenue $25M–$30M (implying recovery from 2025), operating expense $80M–$85M, cash operating expense $50M–$55M, expected year-end cash $30M–$35M, and continued focus on transitioning toward more royalty-driven recurring revenue and trajectory to positive cash flow.
Year-End Liquidity
Ended 2025 with $54M in cash, cash equivalents and short-term investments, providing runway to execute on 2026 plan.
OABI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OABI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $1.81 | ― | ― |
Nov 04, 2025 | $1.48 | $1.42 | -4.05% |
Aug 06, 2025 | $1.93 | $1.88 | -2.59% |
May 08, 2025 | $1.57 | $1.44 | -8.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does OmniAb (OABI) report earnings?
OmniAb (OABI) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is OmniAb (OABI) earnings time?
OmniAb (OABI) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OABI EPS forecast?
OABI EPS forecast for the fiscal quarter 2026 (Q1) is -0.11.